$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
肝癌药多吉美(索拉非尼)的相关问题
2025-10-19 11:44:20
Check Details
临床上常见的肝癌靶向药物
2025-10-19 11:44:20
Check Details
晚期肝癌用药索拉非尼的效果评估
2025-10-19 11:44:20
Check Details
肝癌预防措施
2025-10-19 11:44:20
Check Details
肝癌的早期症状表现
2025-10-19 11:44:20
Check Details
索拉非尼(多吉美)、瑞戈非尼、乐伐替尼患者如何选择?
2025-10-19 11:44:20
Check Details
索拉非尼治疗由乙肝引起的肝癌效果不明显
2025-10-19 11:44:20
Check Details
原发性肝细胞癌使用多吉美可有效延续生存期
2025-10-19 11:44:20
Check Details
出现哪些情况需停用多吉美?
2025-10-19 11:44:20
Check Details
服用多吉美多久会产生耐药?
2025-10-19 11:44:20
Check Details
卡博替尼显著延长晚期肝癌总生存期
2025-10-19 11:44:20
Check Details
乐伐替尼的三大适应症
2025-10-19 11:44:20
Check Details
1
2
...
2551
2552
2553
2554
2555
2556
2557
...
4156
4157
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Lenvatinib Safety Guide: Baseline Assessment & Adverse Reaction Management
2
Inluriyo (Imlunestrant): Oral SERD for ER+/HER2- Breast Cancer with ESR1 Mutations
3
Idelalisib: Oral PI3Kδ Inhibitor for Relapsed/Refractory Hematologic Malignancies
4
Lorlatinib (Lorviqua): Oral Targeted Therapy for ALK-Positive Advanced Non-Small Cell Lung Cancer
5
FDA Approves Ibrance for New Maintenance Indication in HR+/HER2+ Breast Cancer
6
FDA Approves Trodelvy for Two First-Line Indications, Redefining Advanced Triple-Negative Breast Cancer Care
7
Cabozantinib: A Pan-Targeted TKI in Modern Oncology Practice
8
Managing Amivantamab Infusion Reactions: A Clinical Guide for International Practice
9
Onset Timeline and Efficacy Assessment of Margetuximab plus Chemotherapy in HER2-Positive Metastatic Breast Cancer
10
Avutometinib Plus Defactinib: A Precision Therapy for KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer
11
Vemurafenib (Zelboraf) Complete Medication Guide
12
Durvalumab Safety Profile: Managing Immune-Related Adverse Events (irAEs) in Clinical Practice